Highlights
- •Melanoma classification according to the 8th edition American Joint Committee on Cancer (AJCC8) does not improve discriminatory ability compared with the 7th edition American Joint Committee on Cancer (AJCC7).
- •Five-year melanoma-specific survival (MSS) of stages IIB/IIC is lower than that of IIIA.
- •MSS is worse in all substages than results of the International Melanoma Database and Discovery Platform cohort.
Abstract
Objective
The American Joint Committee on Cancer (AJCC) 8th staging system introduced several
revisions. To assess the impact of the 8th edition American Joint Committee on Cancer
(AJCC8) staging system on subgrouping and survival, patients with melanoma from two
tertiary skin cancer centres were classified according to both the 7th edition American
Joint Committee on Cancer (AJCC7) and AJCC8.
Methods
A total of 1948 patients aged ≥18 years with cutaneous melanoma stage II-IV were included.
The impact of sex and age on reclassification was assessed by log binomial models.
The inverse probability of censoring weighting method was used to compute ROC curves
from time-to-event data to assess the discriminatory ability of AJCC7 and AJCC8. Melanoma-specific
survival (MSS) and overall survival (OS) were calculated, and age- and sex-adjusted
MSS hazard ratios were estimated using Cox proportional hazards models.
Results
Of all, 23.5% of patients were assigned a different subgroup when classified according
to AJCC8. Owing to upshifting to stage IIIC (AJCC7 24.8% vs. AJCC8 50.8%), patient
numbers of stages IIIA and IIIB decreased from 28.7% to 16.2% and 46.5% to 28.3%.
The prediction accuracy for AJCC7 and AJCC8 was comparable (integrated time-dependent
area under the curve [AUC] of 0.75 and 0.74, respectively). Five-year MSS of IIB and
IIC AJCC8 was poor and lower than that of IIIA AJCC8 (80%, 67% and 89%, respectively).
Compared to results of the International Melanoma Database and Discovery Platform,
5-year MSS was 10–15% points lower for stages IIC, IIIB and IIIC.
Conclusions
Upshifting affects primarily stage III subgroups, while effects in stage II are minor.
Stage IIB/C (AJCC8) patients have 67–80% MSS and should be considered for adjuvant
treatment, while in stage IIIA, the indication of adjuvant treatment is questionable.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Melanoma. Lancet. 2018; 392: 971-984
- Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.CA Cancer J Clin. 2017; 67: 472-492
- The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K.Br J Dermatol. 2018; 179: 824-828
- Melanoma staging: American Joint committee on cancer (AJCC) 8th edition and beyond.Ann Surg Oncol. 2018; 25: 2105-2110
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma.N Engl J Med. 2018; 378: 1789-1801
- Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.N Engl J Med. 2017; 377: 1813-1823
- Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.N Engl J Med. 2017; 377: 1824-1835
- Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node?.Melanoma Res. 2014; 24: 454-461
- Adopting guidelines into clinical practice: implementation of trastuzumab in the adjuvant treatment of breast cancer in lower saxony, Germany, in 2007.Breast Care (Basel). 2011; 6: 43-50
- Final version of 2009 AJCC melanoma staging and classification.J Clin Oncol. 2009; 27: 6199-6206
- Survival model predictive accuracy and ROC curves.Biometrics. 2005; 61: 92-105
- Evaluating the accuracy of clinical prediction models for binary and survival outcomes.(Paper 2831-2018:)2018
- Scientists rise up against statistical significance.Nature. 2019; 567: 305-307
- External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III.J Clin Oncol. 2018; 36 (abstr 9500)
- Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.Future Oncol. 2019; 15: 359-370
- Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma.Melanoma Res. 2019; 29: 53-58
- Eighth American Joint Committee on Cancer (AJCC) melanoma classification: let us reconsider stage III.Eur J Cancer. 2018 Mar; 91: 168-170
- Vertical growth phase as a prognostic factor for sentinel lymph node positivity in thin melanomas: a systematic review and meta-analysis.Plast Reconstr Surg. 2018; 141: 1529-1540
- Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: a Dutch population-based study.Eur J Cancer. 2018; 92: 100-107
- Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma.J Clin Oncol. 2008; 26: 4296-4303
- Probability of sentinel lymph node positivity in melanoma.Eur J Cancer. 2019; 116: 10-12
- Challenges in sentinel node (SN) pathology in the era of adjuvant treatment: the risk of over- and undertreatment stress the need for expert pathology review.J Clin Oncol. 2019; 37 (abstr 9593)
- Enhancing the prognostic role of melanoma sentinel lymph nodes through microscopic tumour burden characterization: clinical usefulness in patients who do not undergo complete lymph node dissection.Melanoma Res. 2019; 29: 163-171
- Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: findings from the COMBI-AD trial analyzed based on AJCC 8 classification.J Clin Oncol. 2018; 36 (abstr 9591)
- Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.Eur J Cancer. 2019; 116: 148-157
- Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?.Lancet Oncol. 2018; 19: e720-e725
- Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system.Eur J Cancer. 2019; 112: 9-11
- Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis.J Clin Oncol. 2017; 35: 1721-1729
- Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in The Netherlands.Eur J Cancer. 2017; 72: 156-165
Article info
Publication history
Accepted:
June 21,
2019
Received in revised form:
June 17,
2019
Received:
May 19,
2019
Identification
Copyright
© 2019 Elsevier Ltd. All rights reserved.
